Navigation Links
Genisphere Appoints New CEO, Thomas Bliss
Date:6/30/2015

HATFIELD, Pa., June 30, 2015 /PRNewswire/ -- Genisphere announced Tom Bliss has joined the company as CEO to help further develop Genisphere's therapeutics capabilities and portfolio. Mr. Bliss comes with a wealth of partnering experience, having spent much of the last 25 years in leadership positions at biopharmaceutical companies including Therakine, Amgen, Baxter Bioscience, and Johnson & Johnson. Tom started his career in Investment Banking, with a focus on Technology and Biotech Corporate Finance. He graduated from Dartmouth College with a BA in English and Asian Studies (Mandarin), and completed his MBA at The Wharton School, University of Pennsylvania in Finance and Marketing.

Logo - http://photos.prnewswire.com/prnh/20150629/226697LOGO

Tom joins Genisphere as the Company pivots to focus more resources on its emerging therapeutic portfolio, having established its diagnostics business with key strategic partners. "I am excited to start a new challenge with Genisphere, and look forward to working with the team to develop and expand their pharmaceutical collaborations. I know Genisphere has already had substantial success demonstrating our unique 3DNA technology and I'm sure success will accelerate as additional data are generated."  

Dr. Robert Getts, Chief Science Officer, commented, "Tom's wealth of experience and industry knowledge has already made him a key addition to the Genisphere family. Our new innovations led us to look for an experienced leader for our team who will fit in with the company culture, and I'm sure he will make immediate positive contributions." James Kadushin, Chief Operating Officer, said, "I look forward to working with Tom. It is very fortunate that we were able to find someone with deep pharmaceutical development and partnering experience to fulfill this role."

About Genisphere
Genisphere LLC is a targeted drug delivery platform company. Genisphere's platform is a DNA-based nanotechnology called 3DNA®. 3DNA® nanocarriers are used to deliver drugs in a highly targeted manner. Genisphere's technology is IP-protected and fully customizable to deliver a variety of therapeutics including small drugs, biologics, and nucleic acids. 3DNA® nanostructures are composed entirely of DNA, engineered and cross-linked to form a stable architecture while maintaining the biocompatibility of the nucleic acid building blocks. Genisphere has been leveraging a collaborative model to advance its drug delivery platform, and continues to seek partnerships with biotechnology and pharmaceutical companies that could benefit from the company's platform technology. Genisphere is also advancing its own lead compounds based on the 3DNA® platform. For more information, please visit http://genisphere.com

For more information contact:

Dr. Robert Getts
Genisphere 
215-996-3027
Email


'/>"/>
SOURCE Genisphere LLC
Copyright©2015 PR Newswire.
All rights reserved

Related biology news :

1. Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer
2. MedNet Appoints Clareece West As Chief Operating Officer
3. Profil Institute Appoints Dan Bradbury, former Amylin Pharmaceutical CEO, to Board of Directors
4. EyeLock Appoints Roger An Vice President of Global Market Development
5. EyeLock Appoints Michael Fiorito Vice President of Enterprise Accounts
6. EyeLock Appoints Darlene Crumbaugh Vice President of Financial Services
7. Techne Corporation Appoints Dr. J. Fernando Bazan As Chief Technology Officer
8. BioNano Genomics Appoints Dr. Fahim Amini As Vice President Commercial Operations EMEA
9. Homeland Security Corporation (HSCC) Appoints New President with Biometrics and Access Control Solutions Expertise and Contacts
10. Neurobiologist Thomas Jessell to receive $500,000 Gruber Neuroscience Prize
11. Its not all wedded bliss: Marital stress linked to depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2020)... ... March 04, 2020 , ... ... and services, announced it has been nominated as a finalist in the category ... This nomination comes as VGXI expedites manufacturing of a DNA vaccine against the ...
(Date:3/2/2020)... ... ... Toronto-based clinical research organization (CRO) and regulatory consulting firm, dicentra , has announced ... Clarksburg on a farm on Beaver Valley Road. , The owners currently operate an ... it would be a great new option for employees to relocate to. , “Part ...
(Date:2/28/2020)... , ... February 28, 2020 , ... Meridian Clinical ... 2020 Vaccine Industry Excellence (ViE) award for Best Clinical Trial Site. Meridian is ... for the Best Clinical Trial Network award. These nominations were the result of two ...
Breaking Biology News(10 mins):
(Date:3/2/2020)... ... March 02, 2020 , ... McBee, Moore and Vanik ... list in the field of Biotechnology and Organics. , According to statistics compiled by ... of 259 patents issued in technology center 1600 during 2019. Technology center 1600 at ...
(Date:2/21/2020)... (PRWEB) , ... February 20, 2020 , ... In a ... join guest speakers from Synteract including Lisa Dilworth, BS, MS, Vice President ... about these challenges, with feasible strategies and solutions to support patients, sites and sponsors. ...
(Date:2/21/2020)... ... 2020 , ... Join Forrest Brown, Engineering Services Manager – Northeast Region and ... an informative session on Wednesday, February 26, 2020 at 1pm EST to ... facility design to add manufacturing flexibility in the future, especially for CMOs , ...
(Date:2/19/2020)... ... February 18, 2020 , ... Intech , ... of a new and unified global brand identity, as it celebrates its 20th ... challenges, as well as an enthusiasm for designing and manufacturing state-of-the-art medical devices, ...
Breaking Biology Technology: